Clinical Trials Directory

Trials / Unknown

UnknownNCT06076122

Salicornia for Neurovascular Health Improve

Halophyte Plants as a Dietary Supplement to Improve Neurovascular Health

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
350 (estimated)
Sponsor
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla · Academic / Other
Sex
All
Age
18 Years – 99 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is evaluate the effect and safety of the administration of a food supplement based on halophyte plant extracts versus placebo in the neurovascular healthy.

Detailed description

After being informed about the study and giving written informed consent, healthy volunteers (substudy A), patients with transient ischemic attack (TIA) or MINOR stroke (substudy B), patients with cerebral small vessel disease (substudy C) and patients who have suffered a non-disabling stroke and are going to receive carotid angioplasty and stenting (CAS) (substudy D) will be randomized in double-blind manner (participant and investigator) to take a food supplement based on halophyte plant extracts (1 g once a day) or placebo (once a day) for a treatment period of 3 months (substudy A), 11 months (substudy B), 1 year (substudy C) or 7-30 days (substudy D). Participants in substudy A will be twice as likely to be assigned to the experimental treatment as to placebo (2:1 ratio), while those in substudies B, C and D will be equally likely (1:1 ratio).

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTFood supplement based on Salicornia extractsFreshly Salicornia ramosissima plants were recollected. Its aerial part were left to dry and hydroalcoholic extracts were produced by the company Extractos Vegetales S.A. (EVESA) (Cadiz, Spain \[https://evesa.com/\]). The Salicornia extracts were encapsulated by BIO-DIS laboratories (Seville, Spain \[https://www.bio-dis.com/\]), experts in food supplements and certified for such procedures.
DIETARY_SUPPLEMENTPlaceboPlacebo capsules physically equal to the Salicornia extracts capsules

Timeline

Start date
2022-09-15
Primary completion
2023-02-09
Completion
2023-10-31
First posted
2023-10-10
Last updated
2023-10-10

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT06076122. Inclusion in this directory is not an endorsement.